Steven Kenneth Libutti MD

Endocrine, Surgical Oncology (Other than Breast)

Director, Rutgers Cancer Institute of New Jersey, Vice Chancellor Cancer Programs, Rutgers Biomedical and Health Sciences, Senior Vice President Oncology Services, RWJBarnabas Health

Join to View Full Profile

89 Park LnWest Harrison, NY 10604
Phone+1 301-768-8845
Fax+1 732-235-8094

Education & Training

National Institutes of Health Clinical CenterFellowship, Endocrine Surgery, 1995 - 1996
New York Presbyterian Hospital (Columbia Campus)Residency, Surgery, 1990 - 1995
Columbia University Vagelos College of Physicians and SurgeonsClass of 1990, MD, Alpha Omega Alpha
Harvard UniversityAB, Biology, Magna Cum Laude, 1982 - 1986

Certifications & Licensure

NY State Medical License 1992 - 2027
NJ State Medical License 2017 - 2025
American Board of Surgery Surgery

Awards, Honors, & Recognition

PheoPara Alliance Science Award 2012
Top Doctors New York Metro Area 2010-2013
America's Top Doctors 2010-2013
Best Doctors in New York New York Magazine, 2009, 2012-2013
NCI Director's Intramural Innovation Award 2007
NIH Director's Award 2006
NCI Director's Gold Star Award 2006
Federal Technology Transfer Award 2003-2004
Outstanding Service Award National Cancer Institute, 2000
Blakemore Prize for Outstanding Body of Research by a Graduating Chief Resident 1995
U.S. Congressional Citation for Outstanding Contributions to Medicine 1993
First Place 2nd Annual Resident's Research Prize Competition 1993
Second Place 1st Annual Resident's Research Prize Competition 1992
Blakemore Award for Outstanding Research in Surgery 1991-1994
Allen O. Whipple Memorial Prize in Surgery 1990
Samuel and Lewis Rover Award in Genetics and Development 1990
Sandoz Award for Excellence in Biomedical Research 1990
Alpha Omega Alpha Medical Honor Society 1990
William Gerety Cup, Intramural Athletics 1986
John Harvard Scholarship for Excellence in Academics 1985
Scholarship for Excellence in Academics Harvard College, 1983-1984
National Defense Service Medal Department of Defense
Fellow American College of Surgeons
Crisis Response Service Award Commissioned Corps USPHS
Global War on Terrorism Service Medal Department of Defense
Commissioned Corps Training Ribbon Commissioned Corps USPHS
Field Medical Readiness Badge Commissioned Corps USPHS
NIH Director's Award National Institutes of Health
Outstanding Unit Citation Commissioned Corps USPHS
Commendation Medal Commissioned Corps USPHS
Top Doctors New York Magazine
America's Top Doctors for Cancer Castle Connolly
America's Top Doctors Castle Connolly
NCI Director's Innovation Award National Cancer Institute
Join now to see all

Clinical Trials

PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy Start of enrollment: 1998 Oct 01
Completed
Phase 1
Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer Start of enrollment: 1999 Aug 01
Terminated
Phase 2
Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene Start of enrollment: 2003 Sep 01
Completed
Phase 1
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver Start of enrollment: 2004 Jul 01
Completed
Phase 2
TNF-Bound Colloidal Gold in Treating Patients With Advanced Solid Tumors Start of enrollment: 2006 May 01
Completed
Phase 1
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma Start of enrollment: 2007 Apr 01
Terminated
Phase 2
Study of Hair Samples From Patients With Cancer Start of enrollment: 2005 Mar 01
Completed
Gemcitabine and CT-011 for Resected Pancreatic Cancer Start of enrollment: 2012 Sep 01
Terminated
Phase 2
Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors Start of enrollment: 2012 Oct 01
Terminated
Phase 2
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. Start of enrollment: 2012 Nov 01
Completed
Phase 2
QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer Start of enrollment: 2013 Apr 01
Terminated
Phase 1, Phase 2
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Start of enrollment: 2014 Apr 10
Terminated
Phase 2
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers Start of enrollment: 2014 Sep 01
Completed
Phase 2
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19 Start of enrollment: 2020 Apr 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.
Wafik S El-Deiry, Catherine Bresson, Fanny Wunder, Benedito A Carneiro, Don S Dizon
Oncotarget. 2025-03-12
In Memoriam: Remembering Adam Berger, MD-Colleague, Mentor, Friend.
H Richard Alexander, Steven K Libutti, Madalyn Neuwirth
Annals of Surgical Oncology. 2024-12-11
2 citations
Resistant gastroenteropancreatic neuroendocrine tumors: a definition and guideline to medical and surgical management.
Catherine H Davis, Amanda M Laird, Steven K Libutti
Proceedings. 2024-01-01

Journal Articles

Comparison of Bethesda Cytopathology Classification to Surgical Pathology Across Racial‐Ethnic Groups
Bradley A Schiff, Steven K Libutti, Thomas J Ow, Richard V Smith, Juan Lin, Vikas Mehta, Amanda M Laird, Head & Neck
Minimally Invasive Surgery for Pancreatic Neuroendocrine Tumors Results in Shorter Length of Stay
Amanda M Laird, John C Mcauliffe, Steven K Libutti, Journal of The American College of Surgeons
Interferon Alpha Triggers Autoimmune Thyroid Diseases via Lysosomal-Dependent Degradation of Thyroglobulin
Steven K Libutti, Yaron Tomer, The Journal of Clinical Endocrinology and Metabolism
Assessment of tumor growth in pancreatic neuroendocrine tumors in von hippel lindau syndrome
Weisbrod AB, Kitano M, Thomas F, Williams D, Gulati N, Gesuwan K, Liu Y, Venzon D, Turkbey I, Choyke P, Yao J, Libutti SK, Nilubol N, Linehan WM, Kebebew E, J Am Coll Surg, 2/1/2014
Referral Patterns for Endocrine Surgical Disease
Cervera I, Boucai L, Andreopoulou P, Libutti SK, Hughes DT, Endocr Pract, 1/1/2014
Down-Regulation of Filamin A interacting protein 1-like Is Associated with Promoter Methylation and an Invasive Phenotype in Breast, Colon, Lung and Pancreatic Cancers
Kwon M, Lee SJ, Reddy S, Rybak Y, Adem A, Libutti SK, PLoS ONE, 12/1/2013
Evolving paradigm for managing small nonfunctional incidentally discovered pancreatic neuroendocrine tumors
Libutti SK, J Clin Endocrinol Metab, 12/1/2013
Mutation in CDKN2C (p18) and CDKN2D (p19) may cause sporadic parathyroid adenoma
Gluick T, Yuan Z, Libutti SK, Marx SJ, Endocr Relat Cancer, 10/14/2013
Therapy: Blockade of IGF-1R-not effective in neuroendocrine tumours
Libutti SK, Nat Rev Endocrinol, 6/1/2013
Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors
Stevenson R, Libutti SK, Saif MW, JOP, 3/1/2013
Novel agents in gastroenteropancreatic neuroendocrine tumors
Stevenson R, Libutti SK, Saif MW, JOP, 3/1/2013
Pancreatic neuroendocrine tumors: entering a new era
Oberstein PE, Remotti H, Saif MW, Libutti SK, JOP, 3/1/2012
Preoperative Localizing Studies for Initial Parathyroidectomy in MEN1 Syndrome: Is There Any Benefit?
Nilubol N, Weinstein L, Simonds WF, Jensen RT, Phan GQ, Hughes MS, Libutti SK, Marx S, Kebebew E, World J Surg, 2/15/2012
Force or stratagem?
Libutti SK, Inabnet WB 3rd, Surgery, 1/1/2012
Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease
Kitano M, Millo C, Rahbari R, Herscovitch P, Gesuwan K, Webb RC, Venkatesan AM, Phan GQ, Hughes MS, Libutti SK, Nilubol N, Linehan WM, Kebebew E, Surgery, 12/1/2011
Insulinoma: pathophysiology, localization and management
Shin JJ, Gorden P, Libutti SK, Future Oncol, 2/1/2010
Thyroid Cancer: Molecular and Modern Advances
Rosen JE, Libutti SK, Lee SL, J Oncol, 1/1/2010
Targeting TNF-alpha for cancer therapy
Burton ER, Libutti SK, J Biol, 10/23/2009
Development of a clinical decision model for thyroid nodules
Stojadinovic A, Peoples GE, Libutti SK, Henry LR, Eberhardt J, Howard RS, Gur D, Elster EA, Nissan A, BMC Surg, 8/1/2009
Current molecular diagnostics of breast cancer and the potential incorporation of microRNA
Zoon CK, Starker EQ, Wilson AM, Emmert-Buck MR, Libutti SK, Tangrea MA, Expert Rev Mol Diagn, 7/1/2009
Obesity impairs wound healing in ovariectomized female mice
Holcomb VB, Keck VA, Barrett JC, Hong J, Libutti SK, Nunez NP, In Vivo, 7/1/2009
The tumour microenvironment: a novel target for cancer therapy
Hanna E, Quick J, Libutti SK, Oral Dis, 1/1/2009
Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV
Hadi M, Bacharach SL, Whatley M, Libutti SK, Straus SE, Rao VK, Wesley R, Carrasquillo JA, Nucl Med Biol, 5/1/2008
Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma
Koch CA, Brouwers FM, Vortmeyer AO, Tannapfel A, Libutti SK, Zhuang Z, Pacak K, Neumann HP, Paschke R, BMC Cancer, 5/17/2006
Gene promoter methylation in prostate tumor-associated stromal cells
Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM, Woodson KG, J Natl Cancer Inst, 2/15/2006
Join now to see all

Authored Content

My Favorite Sessions from AACR's 2021 Virtual MeetingApril 2021
Minimally Invasive Surgery for Pancreatic Neuroendocrine Tumors Results in Shorter Length of StayOctober 2018
Surface-Modified Shortwave-Infrared-Emitting Nanophotonic Reporters for Gene-Therapy ApplicationsApril 2018

Press Mentions

A $750 Million Effort to Revolutionize Cancer Care in N.J. Opens Next MonthApril 9th, 2025
Becker’s Hospital Review Names RWJBarnabas Health and Rutgers Cancer Institute to 2024’s “100+ Hospitals and Health Systems with Great Oncology Programs" ListNovember 26th, 2024
Rutgers Cancer Institute Treats 200th CAR T-cell Therapy PatientAugust 20th, 2024
Join now to see all

Grant Support

Cancer Center Support GrantRUTGERS BIOMEDICAL AND HEALTH SCIENCES1997–2029
Cancer Center Support GrantRUTGERS BIOMEDICAL AND HEALTH SCIENCES1997–2029
Cancer Center Support GrantRUTGERS BIOMEDICAL AND HEALTH SCIENCES1997–2029
Cancer Center Support GrantRUTGERS BIOMEDICAL AND HEALTH SCIENCES1997–2029
Cancer Center Support GrantRUTGERS BIOMEDICAL AND HEALTH SCIENCES1997–2029
Minibeam Radiation Therapy Enhanced Delivery of Nanoparticle Anticancer Agents to Pancreatic Cancer TumorsUNIV OF NORTH CAROLINA CHAPEL HILL2021–2026
Designing a transcriptome-based, targeted theranostic platform for prostate cancerRUTGERS BIOMEDICAL AND HEALTH SCIENCES2020–2025
Ruth L. Kirschstein T32 Training GrantNational Cancer Institute2015–2020
Deciphering the tissue specificity of MEN1 related tumorigenesisNational Cancer Institute2012–2017
Multifunctional Nanoassemblies for Ligand Directed TherapyNational Cancer Institute2014–2016
Targeting The Tumor Vasculature To Treat CancerNational Cancer Institute2007–2008
Targeting The Tumor Vasculature To Treat CancerDivision Of Clinical Sciences - Nci2001–2006